Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2016 Jan 27

PMID 26811651

Citations 49

Authors

Ramakrishnan Ayloor Seshadri

Olivier Glehen

Affiliations

Soon will be listed here.

Abstract

Gastric cancer associated peritoneal carcinomatosis (GCPC) has a poor prognosis with a median survival of less than one year. Systemic chemotherapy including targeted agents has not been found to significantly increase the survival in GCPC. Since recurrent gastric cancer remains confined to the abdominal cavity in many patients, regional therapies like aggressive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been investigated for GCPC. HIPEC has been used for three indications in GC- as an adjuvant therapy after a curative surgery, HIPEC has been shown to improve survival and reduce peritoneal recurrences in many randomised trials in Asian countries; as a definitive treatment in established PC, HIPEC along with CRS is the only therapeutic modality that has resulted in long-term survival in select groups of patients; as a palliative treatment in advanced PC with intractable ascites, HIPEC has been shown to control ascites and reduce the need for frequent paracentesis. While the results of randomised trials of adjuvant HIPEC from western centres are awaited, the role of HIPEC in the treatment of GCPC is still evolving and needs larger studies before it is accepted as a standard of care.

Citing Articles

Computational Evaluation of Improved HIPEC Drug Delivery Kinetics via Bevacizumab-Induced Vascular Normalization.

Namakshenas P, Crezee J, Tuynman J, Tanis P, Oei A, Kok H Pharmaceutics. 2025; 17(2).

PMID: 40006522 PMC: 11859678. DOI: 10.3390/pharmaceutics17020155.

Optimal hyperthermic intraperitoneal chemotherapy regimen for advanced and peritoneal metastatic gastric cancer: a systematic review and Bayesian network meta-analysis.

Wang T, Ma S, Zhang S, Aizezi Y, Wang Q Front Oncol. 2024; 14:1466473.

PMID: 39600651 PMC: 11588639. DOI: 10.3389/fonc.2024.1466473.

Prediction of surgical benefit in gastric cancer patients with peritoneal metastasis treated with hyperthermic intraperitoneal chemotherapy.

Jin S, Wei Y, Wang Q, Ju Y, Wang Z, Cheng Q Updates Surg. 2024; 76(7):2663-2674.

PMID: 39367285 PMC: 11602788. DOI: 10.1007/s13304-024-01989-y.

Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Acs M, Babucke M, Jusufi M, Kaposztas Z, Slowik P, Hornung M Innov Surg Sci. 2024; 9(1):3-15.

PMID: 38826635 PMC: 11138857. DOI: 10.1515/iss-2023-0055.

Complete Pathologic Response to Gemcitabine and Oxaliplatin Chemotherapy After Prior Therapies in a Patient With Hepatocellular Carcinoma and Peritoneal Metastases Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

Majeed A, Alaparthi S, Halegoua-DeMarzio D, Eberle-Singh J, Jiang W, Anne P World J Oncol. 2024; 15(3):511-520.

PMID: 38751709 PMC: 11092419. DOI: 10.14740/wjon1840.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B . Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2009; 28(1):63-8. DOI: 10.1200/JCO.2009.23.9285. View

Thomassen I, van Gestel Y, van Ramshorst B, Luyer M, Bosscha K, Nienhuijs S . Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2013; 134(3):622-8. DOI: 10.1002/ijc.28373. View

Ishizone S, Maruta F, Saito H, Koide N, Sugiyama A, Nakayama J . Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy. 2006; 52(6):301-7. DOI: 10.1159/000096002. View

Sugarbaker P, Yu W, Yonemura Y . Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003; 21(4):233-48. DOI: 10.1002/ssu.10042. View

Scaringi S, Kianmanesh R, Sabate J, Facchiano E, Jouet P, Coffin B . Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: a single western center experience. Eur J Surg Oncol. 2008; 34(11):1246-52. DOI: 10.1016/j.ejso.2007.12.003. View

Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T . Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988; 61(2):232-7. DOI: 10.1002/1097-0142(19880115)61:2<232::aid-cncr2820610205>3.0.co;2-u. View

Wu C, Lo S, Shen K, Hsieh M, Chen J, Chiang J . Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg. 2003; 27(2):153-8. DOI: 10.1007/s00268-002-6279-7. View

Han T, Kong S, Lee H, Ahn H, Hur K, Yu J . Dissemination of free cancer cells from the gastric lumen and from perigastric lymphovascular pedicles during radical gastric cancer surgery. Ann Surg Oncol. 2011; 18(10):2818-25. DOI: 10.1245/s10434-011-1620-8. View

10.

Yu X, Ren Z, Xue Y, Song H, Wei Y, Li C . D2 lymphadenectomy can disseminate tumor cells into peritoneal cavity in patients with advanced gastric cancer. Neoplasma. 2012; 60(2):174-81. DOI: 10.4149/neo_2013_023. View

11.

Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K . Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg. 1991; 15(4):530-5; discussion 535-6. DOI: 10.1007/BF01675656. View

12.

Mi D, Li Z, Yang K, Cao N, Lethaby A, Tian J . Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials. Int J Hyperthermia. 2013; 29(2):156-67. DOI: 10.3109/02656736.2013.768359. View

13.

Facchiano E, Scaringi S, Kianmanesh R, Sabate J, Castel B, Flamant Y . Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol. 2007; 34(2):154-8. DOI: 10.1016/j.ejso.2007.05.015. View

14.

Hamazoe R, Maeta M, Kaibara N . Intraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer. 1994; 73(8):2048-52. DOI: 10.1002/1097-0142(19940415)73:8<2048::aid-cncr2820730806>3.0.co;2-q. View

15.

Koh J, Yan T, Glenn D, Morris D . Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2008; 16(2):327-33. DOI: 10.1245/s10434-008-0234-2. View

16.

Kim J, Bae H . A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer. 2001; 4(1):27-33. DOI: 10.1007/s101200100013. View

17.

Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S . Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003; 6 Suppl 1:45-9. DOI: 10.1007/s10120-003-0222-y. View

18.

Fujimoto S, Shrestha R, Kokubun M, Kobayashi K, Kiuchi S, Konno C . Positive results of combined therapy of surgery and intraperitoneal hyperthermic perfusion for far-advanced gastric cancer. Ann Surg. 1990; 212(5):592-6. PMC: 1358186. DOI: 10.1097/00000658-199011000-00005. View

19.

Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden P, Haglund U . Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997; 8(2):163-8. DOI: 10.1023/a:1008243606668. View

20.

Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P . Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002; 20(8):1996-2004. DOI: 10.1200/JCO.2002.08.105. View